Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Mutagenesis

Extraordinary collateral mutagenesis induced by CX-5461

Nature Genetics volume 56, pages 12–13 (2024)Cite this article

Subjects

CX-5461 (also known as pidnarulex), currently in phase 1/2 trials, induces selective killing of homologous-recombination-deficient or BRCA1- or BRCA2-mutated tumors in preclinical models. New work confirms these findings but shows it to be a remarkably potent mutagen that induces extensive genetic changes in cultured human cells with or without BRCA1/2 mutations, raising substantial safety issues.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Fugger, K. et al. Trends Cancer 7, 1102–1118 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Chapman, J. R. et al. Mol. Cell 47, 497–510 (2012).

    Article  CAS  PubMed  Google Scholar 

  3. Gourley, C. et al. J. Clin. Oncol. 37, 2257–2269 (2019).

    Article  CAS  PubMed  Google Scholar 

  4. Pilie, P. G. et al. Clin. Cancer Res. 25, 3759–3771 (2019).

    Article  CAS  PubMed  Google Scholar 

  5. Zatreanu, D. et al. Nat. Commun. 12, 3636 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Drygin, D. et al. Cancer Res. 71, 1418–30 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Haddach, M. et al. ACS Med. Chem. Lett. 3, 602–6 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mars, J. C. et al. NAR Cancer 2, zcaa032 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Xu, H. et al. Nat. Commun. 8, 14432 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zimmer, J. et al. Mol. Cell 61, 449–460 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hilton, J. et al. Nat. Commun. 13, 3607 (2022).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  12. Khot, A. et al. Cancer Discov. 9, 1036–1049 (2019).

    Article  CAS  PubMed  Google Scholar 

  13. Koh, G. C. C. et al. Nat. Genet. https://doi.org/10.1038/s41588-023-01602-9 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DSB Repair Metabolism Laboratory, The Francis Crick Institute, London, UK

    Simon J. Boulton

  2. Artios Pharma, Babraham Research Campus, Cambridge, UK

    Simon J. Boulton

Authors
  1. Simon J. Boulton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon J. Boulton.

Ethics declarations

Competing interests

S.J.B. is a co-founder, vice-president of science strategy and a shareholder of Artios Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boulton, S.J. Extraordinary collateral mutagenesis induced by CX-5461. Nat Genet 56, 12–13 (2024). https://doi.org/10.1038/s41588-023-01611-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-023-01611-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing